This data package contains datasets on clinical trials conducted in the United States. Diseases include cervical cancer, diabetes, acute respiratory infection as well as stress. This data package also includes clinical trials registry and results database.

Clinical studies are an important part of drug development globally. The number of registered clinical trials has increased significantly recently. As of November 8, 2024, there were over 515 thousand clinical studies registered globally. The number of clinical studies has increased significantly since there were just 2,119 registered in 2000. In general, clinical trials have grown more complex in recent years and remain vital for the research and development of new drugs and products. Research and development Research and development are an important part of pharmaceutical companies and includes drug development and product development. Among all industry sectors, the pharmaceutical industry spends the largest percentage of their revenue on research and development. Many companies are active in pharmaceutical research and development globally. It is projected Swiss company Roche will remain one of the largest research and development spenders among pharmaceutical companies in the near future. Clinical studies globally Most clinical studies occurring globally are held in countries outside of the U.S. Many clinical trials performed outside the U.S. and EU are done so because it is often easier and cheaper to conduct trials in other locations. Success rates for clinical trials depend heavily on the stage of the trial and the drugs or products being developed. Recent data suggested that only around 29 percent of drugs make it from phase II to phase III.

The clinical trial market is estimated to be US$ 120.97 billion in 2024. From 2024 to 2034, the market is expected to progress at a solid clip, registering a CAGR of 4.3%. By 2034, the clinical trial market is anticipated to have reached a value of US$ 184.61 billion.

Category-wise Outlook

Country-Wise Analysis

The Clinical Trials Market Report is Segmented by Phase (Phase I, Phase II, Phase III, and Phase IV), Design (Treatment Studies and Observational Studies), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Report PDF Offers Values (in USD) for all the Above Segments.

In fiscal year 2023, clinical research funding by the NIH was around 18.9 billion U.S. dollars. This graph shows the actual clinical research funding by the National Institutes for Health (NIH) from FY 2013 to FY 2023 and estimates for FYs 2024 and 2025.

As of November 8, 2024, the number of registered clinical studies in non-U.S. regions stood at some 284 thousand - or 55 percent of all studies worldwide. This statistic shows the distribution of registered clinical studies worldwide by location.

The Clinical Trials Registry and Results Database compiles information on publicly and privately supported clinical trial studies on a wide range of diseases and conditions. Its main goal is to provide an easy access to both privately and publicly funded clinical trials information for patients, their family members, healthcare professionals, researchers, and the public.

Global Clinical Trials Market Size Was Worth USD 53.92 Billion in 2022 and Is Expected to Reach USD 85.01 Billion by 2030, CAGR of 5.93%

The report covers United States Clinical Trials Market and the market is segmented Phase (Phase I, Phase II, Phase III, and Phase IV), By Design (Treatment Studies and Observational Studies), and Geography (United States, Canada, and Mexico). The market provides the value (in USD million) for the above-mentioned segments.

Clinical Research Organization Market 2025: Projected to hit USD 94.61B by 2029 at 9.7% CAGR. Access in-depth analysis on trends, market dynamics, and competitive landscape for data-driven decisions.

The pediatric clinical trial market is anticipated to expand at a CAGR of 5.9% during the projected period. The market value is projected to increase from US$ 17,918.1 million in 2024 to US$ 31,661.0 million by 2034. The market was valued at US$ 16,831.0 million in 2023 and grew at a CAGR of 6.5% from 2019 to 2023.

Category-wise Outlook

Country-wise Analysis

The Clinical Trial Management Systems Market is Segmented by Delivery Mode (On-Premise and Cloud-Based), Component (Software and Services), End-User (Pharmaceuticals, Clinical Research Organizations, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Snapshot img

Clinical Trial Supplies Market Size 2024-2028

The global clinical trial supplies market size is estimated to grow by USD 1.31 billion, at a CAGR of 8.65% between 2023 and 2028.

Biopharma is experiencing significant growth, driven by several key factors. Firstly, there is a rise in the demand for innovative biopharmaceutical products, fueled by advancements in medical research and an increasing focus on personalized medicine. Additionally, government initiatives aimed at promoting clinical research further stimulate industry expansion, providing funding and support for research and development activities and clinical trial support services.
Moreover, the regulation of clinical trials in regional markets ensures compliance with safety and ethical standards, fostering trust and confidence in biopharmaceutical products among healthcare professionals and consumers. These interconnected trends underscore the dynamic landscape of the biopharmaceutical industry, where collaboration between government agencies, research institutions, and industry stakeholders drives innovation and advances healthcare outcomes. As regulatory frameworks evolve and investment in research increases, the market for biopharmaceuticals is poised for continued growth, offering opportunities for improved treatments and medical breakthroughs in various therapeutic areas.

What will be the Size of the Clinical Trial Supplies Market During the Forecast Period?

To learn more about this market report, Download Report Sample

The global clinical trial supply market is experiencing a period of rapid evolution, driven by a combination of factors, including increasing complexity of clinical trials, advancements in technology, and growing demand for clinical research services. Key trends shaping the industry include a shift towards outsourcing of clinical trial supply chain activities, the growing importance of data management and analytics, and a focus on risk mitigation and continuity planning. As clinical trials become more complex and global in scope, there is a rising demand for specialized clinical trial supply services, including sourcing, logistics, and storage of clinical trial materials. Clinical trial supply forecasting has become a crucial aspect of this market, allowing for more accurate predictions in terms of demand, inventory management, and distribution to avoid costly delays and shortages.
Biopharmaceutical companies are increasingly seeking efficient clinical trial supply management strategies to ensure timely delivery of biological drugs to clinical sites worldwide. The clinical trial supplies industry plays a pivotal role in meeting these needs by ensuring that the required materials are available when and where they are needed, with a focus on minimizing waste and optimizing inventory levels. Supply chain management in clinical trials is becoming more sophisticated, driven by the increasing need to manage and coordinate resources across different regions and time zones. Additionally, the growing emphasis on biological drugs in clinical research has led to new challenges in sourcing and transporting temperature-sensitive materials.
The Clinical Trial Supplies Market is evolving with the increasing demand for regulatory-compliant logistics and cold chain distribution to ensure the safe delivery of trial materials. Comparator drug sourcing and direct-to-patient shipments are becoming more common, supported by decentralized trial support systems. Real-time tracking solutions and digital supply management are enhancing transparency and efficiency across the supply chain. GMP-certified packaging and temperature-controlled storage ensure the integrity of biologics trial supplies. Adaptive trial supply strategies, just-in-time inventory, and on-demand labeling solutions are optimizing resource allocation. Blockchain traceability further improves supply chain security, while decentralized models and advanced logistics capabilities continue to shape the future of clinical trials.

How is the Clinical Trial Supplies Market Segmented?

The clinical trial supplies market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

End-user

  Pharmaceutical industry
  Biologics industry
  Medical device industry


Type

  Phase III
  Phase II
  Phase IV and BE/BA studies
  Phase I


Service

  Manufacturing
  Packaging and Labeling
  Storage and Distribution
  Comparator Sourcing
  Ancillary Supplies
  Others


Therapeutic Area

  Oncology
  Cardiovascular Diseases
  Neurology
  Infectious Diseases
  Metabolic Disorders
  Others


Distribution Channel

  Direct-to-Site
  Depot-to-Site
  Others


Geography

  North America

    US
    Canada
    Mexico


  Europe

    Germany
    UK
    France

N – sample size; * – these items were late additions to the survey hence the smaller sample size.

1 The number of registries that provide data to the ICTRP has increased from nine to fifteen in between 2008/2009 and 2012. Registry acronyms stand for: ClinicalTrials.gov (CT.gov), Japan Primary Registries Network (JPRN), Iranian Registry of Clinical Trials (IRCT), Australian New Zealand Clinical Trials Registry (ANZCTR), EU Clinical Trials Register (EU-CTR), International Standard Randomized Controlled Trial Number Register (ISRCTN), Chinese Clinical Trial Register (ChiCTR), Clinical Trials Registry - India (CTRI), German Clinical Trials Register (DRKS), The Netherlands National Trial Register (NTR), Clinical Research Information Service (CRiS) Republic of Korea, Pan African Clinical Trial Registry (PACTR), Cuban Public Registry of Clinical Trials (RPCEC), Sri Lanka Clinical Trials Registry (SLCTR) and Brazilian Clinical Trials Registry (ReBec).2 Other sponsors consisted of persons that were registered as primary sponsor, non-governmental organizations, collaborative research institutions and clinical research organizations.3 Overlap was possible, total in this category was greater than 731 in 2008/2009 and greater than 386 in 2012.4 Genetic interventions consisted of gene transfer therapy and somatic cell transplants.5 The presence of study phase in records was analysed separately for trials in drugs, biologicals or vaccines. 2008/2009: Of 439 trials researching these types of interventions, study phase was reported in 370 records (84.3%). 2012: Of 221 trials researching these types of interventions, study phase was reported in 172 records (77.8%).

As of April 2024, Brazil led the ranking of Latin American countries with most clinical trials, with close to 10,000 studies. Mexico ranked second, with nearly 5,000 clinical trials. Brazil concentrated 4.3 percent of the clinical trials performed worldwide regarding infectious diseases in 2021.

The National Database for Clinical Trials Related to Mental Illness (NDCT) is an extensible informatics platform for relevant data at all levels of biological and behavioral organization (molecules, genes, neural tissue, behavioral, social and environmental interactions) and for all data types (text, numeric, image, time series, etc.) related to clinical trials funded by the National Institute of Mental Health. Sharing data, associated tools, methodologies and results, rather than just summaries or interpretations, accelerates research progress. Community-wide sharing requires common data definitions and standards, as well as comprehensive and coherent informatics approaches for the sharing of de-identified human subject research data. Built on the National Database for Autism Research (NDAR) informatics platform, NDCT provides a comprehensive data sharing platform for NIMH grantees supporting clinical trials.

The clinical trials market size was valued at USD 52.92 billion in 2024 and is expected to reach USD 120 billion by 2037, registering around 6.5% CAGR during the forecast period i.e., between 2025-2037. North America industry is estimated to hold largest revenue share by 2037, attributed to rising number of clinical trial studies in the region.

The Report Covers Europe Clinical Trials Market Share and It is Segmented by Phase (Phase I, II, III, and IV), Design (Treatment Studies (Randomized Control Trial, Adaptive Clinical Trial, and Non-Randomized Control Trial), and Observational Studies (Cohort Study, Case-Control Study, Cross-Sectional Study, and Ecological Study), and Geography (Germany, United Kingdom, France, Italy, Spain and Rest of Europe). The Market Forecasts and Revenues are Provided in Terms of Value in USD Million for the Above Segments.

Healthcare Contract Research Outsourcing Market size was valued at USD 43.22 Billion in 2024 and is projected to reach USD 75.66 Billion by 2031, growing at a CAGR of 7.25% during the forecast period 2024-2031.

Global Healthcare Contract Research Outsourcing Market Drivers

The market drivers for the Healthcare Contract Research Outsourcing Market can be influenced by various factors. These may include:

Increasing Research and Clinical Trial Involvement: There has been an increase in research and development activity in the biotechnology and pharmaceutical sectors, which has raised the need for clinical trial outsourcing. Healthcare CROs are essential to the success of these trials and the expansion of the market as a whole.

Time savings and cost effectiveness: Drug development can proceed more quickly and with lower operating expenses for pharmaceutical and biotech businesses that outsource their clinical research operations to CROs. CROs frequently have specialized infrastructure and knowledge, which boosts productivity and shortens turnaround times.

Global Clinical Trials Industry: The increasing number of clinical trials being done in different parts of the world has led to the demand for CROs with local knowledge who can manage a variety of trial populations and negotiate regulatory environments.

The intricacy of the drug development process: With developments in personalized medicine, genetics, and medical research, the process of developing new drugs has grown increasingly intricate. To take use of CROs’ specialized resources and skills, pharmaceutical corporations outsource different parts of clinical trials to them.

Strategic Emphasis on Fundamental Skills: Many biotech and pharmaceutical businesses would rather outsource their clinical research operations to specialized CROs and concentrate on their core skills, such marketing and drug discovery. They are able to distribute resources more skillfully as a result.